

# Maternally Inherited Essential Hypertension: Adding Further Complexity to an Already Complex Condition

Christian Delles<sup>1,✉</sup>

Hypertension is a complex clinical condition characterized by raised blood pressure. Apart from personal and environmental factors a genetic component of hypertension is well recognized. Heritability is estimated at 15%–40%.<sup>1</sup>

In order to unravel the genetic factors that contribute to blood pressure regulation, and hence to hypertension, a multitude of strategies have been employed, driven by advances in understanding of our genetic make-up, technology, and our understanding of pathophysiology. Candidate gene approaches were among the first, in hindsight slightly naive, attempts to study the genetic component of hypertension. They were based on the assumption of strong effects of genetic variants on blood pressure, and the simplistic conception that genetic variation will be limited to or at least focused on major effectors such as vasoactive substances and their receptors. At a time when technology allowed first genome-wide approaches to undertake unbiased studies,<sup>2,3</sup> there was considerable disappointment that “blood pressure genes” were not readily detected.<sup>4</sup> We have since learned that effect sizes are much smaller than originally thought, that there are hundreds if not thousands of genetic variants associated with blood pressure regulation, and that they often affect genes that encode signaling and regulatory proteins, or are located in parts of the genome that do not directly relate to a specific gene or exon.<sup>5</sup>

However, there have been other strategies. Mendelian forms of hypertension allowed researchers to better understand the mechanisms of blood pressure regulation, and in particular the role of the kidneys. Renal electrolyte transport has long been recognized as being tightly linked to blood pressure, and sequencing the genes that encode transporter proteins has indeed led to the discovery of new genetic variants that would not have been detected by genome-wide association studies.<sup>6</sup> Similarly, in patients with some forms of secondary hypertension such as those with aldosterone-producing adenomas, studies of somatic mutations have led to better understanding of the genotype/phenotype association and thereby pathophysiology.<sup>7</sup> These approaches are often based on clinical observations, thorough examination of patients and careful workup of genetic material from index patients and their family members.

In this issue of the *Journal*, Guo *et al.*<sup>8</sup> describe 2 novel mitochondrial DNA variants that are associated with maternally inherited essential hypertension. They studied a family across 3 generations including the index patient, her 3 siblings, and their offspring. The index patient came to the authors' attention because of onset of severe hypertension at young age, associated with metabolic changes including high triglyceride and low-density lipoprotein-cholesterol and low high-density lipoprotein-cholesterol levels. Magnesium levels were found to be low, and there were additional cardiovascular phenotypes including arterial stiffening, changes in left ventricular function and impaired exercise tolerance. There were further cases of such unusual hypertension in the family, and the pedigree suggested that the trait is being passed on from mothers to their offspring, implying mitochondrial inheritance. Sequencing of the entire mitochondrial genome led to the discovery of a potentially pathogenic variant in the *MT-TP* gene (m. 15992 A>G) and a nonsynonymous variant in the *MT-CYB* gene (m. 15077 G>A) that acts in synergism and could explain the observed phenotype. The former gene encodes the mitochondrial tRNA that transfers proline in protein synthesis, and the variant has the potential to reduce proline recognition efficiency of this tRNA.

The mitochondrial genome is unique in that it encodes some of the key players involved in mitochondrial function, namely energy generation, but that it relies on the cell's complex apparatus to complete the cycle from genetic information to transcription and translation into protein.<sup>9</sup> Numerous variants in the mitochondrial genome that are associated with maternally inherited essential hypertension have been described, and many of them affect genes encoding for tRNAs.<sup>10</sup>

tRNAs are complex molecules that in the first instance enable protein biosynthesis by decoding the transcript and translating it into amino acids. Depending on the position of a genetic variation within tRNAs the efficiency of protein biosynthesis can be altered in numerous ways, with the potential to even result in altered amino acid sequence.<sup>10</sup> However, it has been increasingly recognized that tRNAs play roles beyond translation of mRNA into protein, and these include regulatory

Correspondence: Christian Delles ([Christian.Delles@glasgow.ac.uk](mailto:Christian.Delles@glasgow.ac.uk)).

Initially submitted August 20, 2021; accepted for publication August 24, 2021; online publication August 24, 2021.

<sup>1</sup>Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.

<https://doi.org/10.1093/ajh/hpab133>

© American Journal of Hypertension, Ltd 2021. All rights reserved. For Permissions, please email: [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

functions akin (yet mechanistically different) to those of non-coding RNA species such as microRNAs.<sup>11</sup> This explains why the effects of changes in tRNAs are not entirely predictable and to some extent occur at random, depending on changes in protein sequence and the regulatory functions of tRNAs. It is also not surprising that in the family characterized by Guo *et al.*<sup>8</sup> the key variant m. 15992 A>G is modified by another variant (m. 15077 G>A). And equally unsurprisingly, the clinical phenotypes associated with tRNA mutations can include a wide range of different traits.

Patients in the family studied by Guo *et al.*<sup>8</sup> not only have early onset hypertension but also reduced exercise tolerance and left ventricular remodeling. Whether these are genuine effects of the genetic alterations or secondary to severe hypertension remains unclear. More strikingly, a metabolic phenotype characterized by an unfavorable lipid profile in these patients could well be related to changes in mitochondrial function and has been found in other patients with mitochondrial DNA mutations.<sup>10</sup> Patients are also characterized by hypomagnesaemia and while the mechanisms linking the genetic variants to magnesium homeostasis remain unclear the key role of Mg<sup>2+</sup> for mitochondrial function<sup>12</sup> and the pathophysiological links between Mg<sup>2+</sup> transporters and hypertension<sup>13</sup> are evident.

Variants in tRNAs remind us of the complex nature of protein biosynthesis and that the link between a gene and the resulting protein is less tight than originally proposed. With defects in the protein synthesizing machinery, genetic code cannot be translated correctly into protein. Moreover, we have also learned about the role of posttranslational modifications of proteins that affect their structure, trafficking, and function. Such modifications can be altered as a result of variants within the gene encoding the protein but also as a result of other processes that lead to glycosylation, oxidation, palmitoylation, or other changes to proteins. For example, we recently demonstrated different forms of uromodulin in the urine of normotensive and hypertensive pregnant rats<sup>14</sup> and there are good reasons to believe that this protein undergoes posttranslational modifications that lead to impaired trafficking, sorting, and endoplasmic reticulum stress.<sup>15</sup> Obviously, the picture becomes even more complicated with tRNA variants that affect proteins already during biosynthesis.

Where does the paper by Guo *et al.*<sup>8</sup> lead us? To be honest, probably not very far. They describe yet another mitochondrial DNA variation and another possible explanation for maternally inherited essential hypertension. The exact functional consequences of the described variants remain as unclear as those of the myriad nuclear DNA variants that have been discovered by genome-wide association and DNA sequencing studies. The authors remind us, however, that hypertension is far more than simple changes in vasomotor function or volume homeostasis. Compared with the already impenetrable model of hypertension that Guyton drew in 1972<sup>16</sup> we begin to realize that hypertension is considerably more complex. Mitochondrial tRNA variants are yet another piece in this ever evolving jigsaw.

On a more general note, the paper by Guo *et al.*<sup>8</sup> is the result of careful clinical observation and meticulous workup of clinical and molecular characteristics of members of a

large family. Many of us, including myself, will ask themselves if they would have detected this constellation in their own practice. With all the pressures on clinical services, the assumption that hypertension is a straightforward condition that can generally be managed in primary care, and the impression of stakeholders and funding bodies that hypertension is not as “trendy” as other cardiovascular conditions, who would have the time to draw a detailed pedigree to recognize an unusual pattern of inheritance? And who would have the resources to phenotype family members and dissect the underlying genetic variant? The study by Guo *et al.*<sup>8</sup> underscores that it is important and satisfying to remain curious, and that hypertension is anything but boring.

## FUNDING

Dr Delles is supported by grants from the British Heart Foundation (RE/18/6/34217) and the European Commission (reference 954798).

## DISCLOSURE

The author declared no conflict of interest.

## REFERENCES

- Delles C, McBride MW, Graham D, Padmanabhan S, Dominiczak AF. Genetics of hypertension: from experimental animals to humans. *Biochim Biophys Acta* 2010; 1802:1299–1308.
- Caulfield M, Munroe P, Pembroke J, Samani N, Dominiczak A, Brown M, Benjamin N, Webster J, Ratcliffe P, O’Shea S, Papp J, Taylor E, Dobson R, Knight J, Newhouse S, Hooper J, Lee W, Brain N, Clayton D, Lathrop GM, Farrall M, Connell J; MRC British Genetics of Hypertension Study. Genome-wide mapping of human loci for essential hypertension. *Lancet* 2003; 361:2118–2123.
- Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. *Nature* 2007; 447:661–678.
- Harrap SB. Where are all the blood-pressure genes? *Lancet* 2003; 361:2149–2151.
- Padmanabhan S, Dominiczak AF. Genomics of hypertension: the road to precision medicine. *Nat Rev Cardiol* 2021; 18:235–250.
- Ji W, Foo JN, O’Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW, Levy D, Lifton RP. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. *Nat Genet* 2008; 40:592–599.
- Zhou J, Azizan EAB, Cabrera CP, Fernandes-Rosa FL, Boulkroun S, Argentesi G, Cottrell E, Amar L, Wu X, O’Toole S, Goodchild E, Marker A, Senanayake R, Garg S, Åkerström T, Backman S, Jordan S, Polubothu S, Berney DM, Gluck A, Lines KE, Thakker RV, Tuthill A, Joyce C, Kaski JP, Karet Frankl FE, Metherell LA, Teo AED, Gurnell M, Parvanta L, Drake WM, Wozniak E, Klinzing D, Kuan JL, Tiang Z, Gomez Sanchez CE, Hellman P, Foo RSY, Mein CA, Kinsler VA, Björklund P, Storr HL, Zennaro MC, Brown MJ. Somatic mutations of GNA11 and GNAQ in CTNNB1-mutant aldosterone-producing adenomas presenting in puberty, pregnancy or menopause. *Nat Genet* 2021; e-pub ahead of print. (doi:10.1038/s41588-021-00906-y)
- Guo H, Yuan Y, Kiang XY, Guo L, Bu R. Co-occurrence of m.15992A>G and m.15077G>A is associated with high penetrance of maternally inherited hypertension in a Chinese pedigree. *Am J Hypertens* 2021.
- D’Souza AR, Minczuk M. Mitochondrial transcription and translation: overview. *Essays Biochem* 2018; 62:309–320.

10. Liu Y, Chen Y. Mitochondrial tRNA mutations associated with essential hypertension: from molecular genetics to function. *Front Cell Dev Biol* 2020; 8:634137.
11. Schimmel P. The emerging complexity of the tRNA world: mammalian tRNAs beyond protein synthesis. *Nat Rev Mol Cell Biol* 2018; 19:45–58.
12. Pilchova I, Klacanova K, Tatarkova Z, Kaplan P, Racay P. The involvement of Mg<sup>2+</sup> in regulation of cellular and mitochondrial functions. *Oxid Med Cell Longev* 2017; 2017:6797460.
13. Antunes TT, Callera GE, He Y, Yogi A, Ryazanov AG, Ryazanova LV, Zhai A, Stewart DJ, Shrier A, Touyz RM. Transient receptor potential melastatin 7 cation channel kinase: new player in angiotensin II-induced hypertension. *Hypertension* 2016; 67:763–773.
14. Mary S, Small HY, Siwy J, Mullen W, Giri A, Delles C. Polymerization-incompetent uromodulin in the pregnant stroke-prone spontaneously hypertensive rat. *Hypertension* 2017; 69:910–918.
15. Boder P, Mary S, Mark PB, Leiper J, Dominiczak AF, Padmanabhan S, Rampoldi L, Delles C. Mechanistic interactions of uromodulin with the thick ascending limb: perspectives in physiology and hypertension. *J Hypertens* 2021; 39:1490–1504.
16. Guyton AC, Coleman TG, Granger HJ. Circulation: overall regulation. *Annu Rev Physiol* 1972; 34:13–46.